

# Review of: "[Case Report] Profound Symptom Alleviation in Long-Covid Patients After PAMP-Immunotherapy: Three Case Reports"

Mohammad Abul Hasnat<sup>1</sup>

<sup>1</sup> Shahjalal University of Science and Technology

Potential competing interests: No potential competing interests to declare.

Dear authors,

The case reports are really interesting, but due to the lack of information about the specificity of the mode of actions of PAMP-immunotherapy, there is no more scientific vigor in this case report at this time, I think. Moreover, PAMP-immunotherapy is a rare treatment method and is not allowed in most areas of the world; even it's very uncertain to study it using animal models, so how could this non-specific PAMP-immunotherapy help in research to make sure of its specific mode of action? This is a big question. Before publication, major revision is mandatory.

Anyway, I would like to request the authors to improve the case report in the following points-

1. In the introduction portion, more information and references are needed.
2. Please mention the type of cancer against which PAMP-immunotherapy was applied in the beginning.
3. Requesting to mention the microbe's name or the extracted components from them that were used in PAMP-immunotherapy.
4. How the patients took/received the therapy? Please mention.
5. Need to mention the doses.
6. Not only the 14 questions, but also the previous long clinical history of the patients need to be considered to analyze and improve the case study before publication.
7. Authors need to notice the side effects of the PAMP-immunotherapy, if any.
8. According to Table 1, patients JS (1954) and RJH (1963) were older than patient 1, ARM (1978), but the percentage of improvement is high in them, although the younger has stronger immunity than the elder generally. Please could you explain it in the discussion?
9. In the discussion, more references are needed and it needs to be discussed more briefly.
10. In references, should avoid the unnecessary signs.

Regards,

Mohammad Abul Hasnat

